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Background: Therapeutic cancer chemotherapy is most successful when complete dosing is 
achieved. Because many newer therapeutic agents are oral and self-administered by the patient, 
adherence is a concern. The purpose of our analysis was to explore relationships between adher-
ence, patient characteristics, and barriers to adherence.
Methods: This secondary analysis utilized self-reported data from a randomized trial of self-care 
management conducted at two cancer centers in the US. Symptom distress was measured using the 
15-item Symptom Distress Scale (SDS-15) and depression with the Patient Health Questionnaire-9 
(PHQ-9). Adherence to oral medication was self-reported using the 8-item Morisky Medication 
Adherence Scale (MMAS-8). Measures were collected via Web-based, study-specific software 
~8 weeks after treatment start date. Odds of low/medium adherence (score ,8) were explored 
using univariate logistic regression. Given the number of factors and possible relationships among 
factors, a classification tree was built in lieu of a multivariable logistic regression model.
Results: Of the eligible participants enrolled, 77 were on oral therapy and 70 had an MMAS 
score. Forty-nine (70%) reported a high adherence score (=8). Higher odds of low/medium 
adherence were associated with greater symptom distress (P=0.09), more depression (P=0.05), 
chemotherapy vs hormonal oral medication (P=0.03), being female (P=0.02), and being 
randomized to the control group in the parent trial (P=0.09). Conversely, high adherence was 
associated with working (P=0.08), being married/partnered (P=0.004), and being older (P=0.02). 
Factors identified as significantly related to low/medium adherence from the univariate logistic 
regression analyses were supported by the classification tree results.
Conclusion: Nonadherence to therapeutic oral medications in patients with cancer was asso-
ciated with being unmarried/unpartnered, symptom distress, younger age, not working, and 
female sex. These findings may help to identify patients at risk for nonadherence and for whom 
supportive interventions to enhance adherence may be needed.
Keywords: patient-centered technology, self-management, logistic regression, recursive 
partitioning
Introduction
Much attention has been focused on patient adherence to oral chemotherapy, pri-
marily prompted by the increasing clinical use of approved and experimental oral 
targeted therapies. Successful chemotherapy is best achieved by complete dosing of 
the prescribed agent whether it be an intravenous infusion in the clinic or a patient-
administered oral medication.1 The Clinical Journal of Oncology Nursing dedicated 
an entire issue to the topic in June 2015, and the American Society of Clinical 
Oncology and the Oncology Nursing Society published comprehensive guidelines 
covering the safety and administration of oral chemotherapy in 2013.2 Furthermore, 
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various other types of therapeutic oral medications 
(eg, antiestrogens, antiandrogens) or those intended to 
prevent severe toxicities (eg, allopurinol) are prescribed 
to patients with cancer. Clinical investigators have studied 
adherence since the 1980s3 with varying results. Authors of 
systematic reviews4–6 have identified factors that interfere 
with, or promote, patient adherence to oral medications. 
Factors relevant to the characteristics of the patient, the 
regimen, and its side effects, as well as the institutional and 
home environments, have been implicated. Johnson4 listed 
factors that promoted adherence with large effect sizes when 
studied, identifying positive provider relationships, low 
side-effect profiles, high knowledge levels about the medi-
cations, and family support. Mathes et al5 discussed the fact 
that oral agent side effects are not always strong predictors 
of low adherence. A number of programs of research have 
focused on developing interventions to improve or ensure 
adherence to oral medications.7,8 More recently, Spoelstra 
and Sansoucie9 classified interventions that were “recom-
mended for practice” based on strong evidence for promoting 
adherence that included patient monitoring, feedback, and 
interventions combining patient education and support with 
various methods of reminders, packaging, and feedback.
While conducting a randomized trial10 of a Web-based, 
patient-centered, educational intervention during active cancer 
therapy in which symptom distress was a primary outcome, we 
took the opportunity to assess adherence to oral medications. 
The trial was approved by the Dana-Farber/Harvard Cancer 
Center Institutional Review Board. The purpose of this analy-
sis was to explore oral agent adherence in relationship to the 
study group, cancer symptoms, type of agent, psychosocial 
measures, and selected demographic variables.
Methods
sample and procedures
This secondary analysis utilized self-reported data from 
the randomized Electronic Self-Report Assessment for 
Cancer (ESRA-CII) trial conducted at two comprehensive 
cancer centers. The details of the trial have been reported 
elsewhere.10 To summarize, a total of 779 adult, ambula-
tory patients with cancer of any type who had started a new 
therapeutic regimen were enrolled and randomized; 752 
were deemed eligible. All participants used the Web-based 
ESRA-C to self-report symptoms and quality of life prior 
to starting a new cancer therapy (T1), at 3–6 weeks (T2), 
6–8 weeks after T2 (T3), and at the end of the therapeutic 
regimen (T4). The intervention group participants were 
presented with teaching tips for symptoms and quality of life 
issues (SxQOL), which were reported above a predetermined 
threshold. The education included why and how often a 
particular SxQOL happens, what to do at home for self-
care, and when to call the clinic. Monitoring and tracking 
of SxQOL was available to the intervention group as well, 
within the ESRA-C program.
Measures
Symptom distress was measured using the 15-item Symptom 
Distress Scale (SDS-15)10,11 and depression with the Patient 
Health Questionnaire (PHQ-9).12,13 Participants who were 
prescribed any type of therapeutic oral agent were identified 
by medical record review. Adherence to oral medication 
was collected at T3 using the 8-item Morisky Medication 
Adherence Scale (MMAS-8)14 adapted to the cancer setting.15 
Two patients were given the MMAS-8 at T4 and the corre-
sponding symptom measures were used. An additional adher-
ence item was asked, with the permission of the MMAS-8 
creators, to evaluate overadherence.
Analytic procedure
The T3 data for adherence, symptom distress, and depression 
were analyzed among participants on oral therapy. The fre-
quency with which participants indicated a nonadherent behav-
ior was summarized for each item in the MMAS-8 scale and 
the additional item. The overadherence item was not used in 
the computation of the overall adherence score. The MMAS-8 
score was categorized into low/medium (score ,8) and high 
(score =8) adherence.14 The odds of low/medium adherence 
were explored univariately using logistic regression. On the 
basis of previous research, our factors of interest included the 
following: SDS-15 summed score, PHQ-9 summed score, 
months on oral medication, therapy type (chemotherapy vs 
hormonal), sex, stage (IV vs 0-III), study group, work status, 
education (# high school vs . high school), minority status, 
relationship status (married/partnered vs not), and age.
Given the small sample size relative to the number of 
factors and possible relationships among factors, a classifi-
cation tree subsequently was built in lieu of a multivariable 
logistic regression model. Classification trees comprise a 
nonparametric approach that performs well when there is 
a complex relationship between the factors and outcome.16 
Recursive partitioning was implemented to build the classifi-
cation tree exploring the most influential factors related to low/
medium adherence using the Rpart functionality in R.17 The 
tree was built by first identifying the factor that best split the 
data into low/medium-adherence and high-adherence nodes. 
Each node had the potential to be split again if the sample 
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size was adequate and the split was considered beneficial. 
The minimum number of participants required in a node to 
consider a further split was 15 participants. A terminal node 
was defined when no further splits occurred. Rpart uses 
the Gini index setting to determine if a split is beneficial.17 
The default ten cross-validations were conducted with the 
procedure. The classification rate, or proportion of correct 
classifications divided by the number of observations in a 
node, was calculated for each terminal node. All analyses 
were performed in SAS Version 9.2 and R 2.15.2. Due to the 
exploratory nature of this analysis, a significance level of 0.1 
was used to explore a relationship among study variables.
Results
Of the 752 eligible participants enrolled in the randomized 
trial, 77 were on oral therapy at T3, and 70 of these had an 
MMAS score. Patient characteristics are provided in Table 1 
for those on oral therapies with an adherence score. Among 
the 70 participants, 42 (60%) were male, age ranged from 
34 years to 80 years (median =61 years), and 22 (31%) 
had stage IV disease. The most common cancer diagnoses 
included 31 prostate (44%) and 19 breast (27%). Forty-nine 
(70%) reported an adherence score of 8.0, indicating high 
adherence. High adherence was reported in 16 of 29 (55%) 
participants taking oral chemotherapy and 33 of 41 (80%) 
taking hormonal medications. The most frequent reason why 
a participant did not adhere was forgetting to take the oral 
medication (Table 2). Only one participant reported taking 
more than the prescribed dose.
The results from the univariate analyses (Table 3) suggest 
that higher odds of low/medium adherence were associated 
with higher symptom distress (P=0.09), higher depression 
Table 1 Patient characteristics for all (n=70) and for those with self-reported low/medium adherence and high adherence to oral 
cancer medications
Patient characteristic Overall N (%) Low/medium adherence High adherence
N (%) N (%)
n 70 21 49
Age, median (range), years 61 (34–80) 56 (34–75) 62 (39–80)
Minority 9 (14) 3 (14) 6 (12)
sex
Male 42 (60) 8 (38) 34 (69)
Female 28 (40) 13 (62) 15 (31)
study group
control 39 (56) 15 (71) 24 (49)
intervention 31 (44) 6 (29) 25 (51)
cancer type
Breast 19 (27) 6 (29) 13 (27)
colorectal 1 (1) 1 (5) 0 (0)
Other gi 6 (9) 2 (10) 4 (8)
Prostate 31 (44) 6 (29) 25 (51)
renal cell 6 (9) 3 (14) 3 (6)
sarcoma 5 (7) 2 (10) 3 (6)
Other 2 (3) 1 (5) 1 (2)
Therapy type
chemotherapy 29 (41) 13 (62) 16 (33)
hormonal therapy 41 (59) 8 (38) 33 (67)
Months on oral agents, median (range) 2.27 (0.39–14.01) 2.10 (0.46–14.01) 2.34 (0.39–4.70)
stage
0 2 (3) 2 (10) 0 (0)
1 8 (11) 2 (10) 6 (12)
2 27 (39) 3 (14) 24 (49)
3 10 (14) 4 (19) 6 (12)
4 22 (31) 9 (43) 13 (27)
True missing* 1 (1) 1 (5) 0 (0)
Working (n=62) 40 (65) 8 (47) 32 (71)
education (n=69)
#hs 12 (17) 4 (20) 8 (16)
.hs 57 (83) 16 (80) 41 (84)
Married/partnered 61 (87) 14 (67) 47 (96)
Note: *indicates a non-solid tumor.
Abbreviations: gi, gastrointestinal; hs, high school.
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(P=0.05), taking chemotherapy vs hormonal oral medication 
(P=0.03), being female (P=0.02), and being randomized to 
the control group (P=0.09). Conversely, the odds of high 
adherence were associated with working (P=0.08), being 
married/partnered (P=0.004), and being older (P=0.02).
The factors identified as significantly related to the odds 
of low/medium adherence from the univariate logistic regres-
sion analyses were supported by the classification tree results. 
Five splits and six terminal nodes were generated, in which 
nodes 1, 3, and 5 indicated low/medium adherence (Figure 1). 
Node 1 was defined by relationship status, specifically not 
married or partnered. For those who were married/partnered, 
Node 3 was defined by high symptom distress (SDS-15 $20) 
and age ,46 years. For those married/partnered and with 
lower symptom distress, Node 5 was defined by not working 
and being female. The classification rates ranged from 0.67 
to 1.00 across the six terminal nodes.
Discussion
In a sample of participants undergoing active cancer therapy, 
we found univariate evidence of associations with oral 
medication adherence, which included lack of a spouse/
partner, symptom distress, younger age, not working at the 
start of therapy, female sex, and oral chemotherapy vs oral 
hormonal medications. Our classification results suggest 
that significant relationships exist between adherence and 
symptom distress, age, working status at the start of therapy, 
sex, and relationship status.
Studies in oral agents for cancer treatment have docu-
mented findings similar to ours. Lebovits et al18 evaluated 
adherence to oral cytoxan and prednisone in women with 
breast cancer and found significant associations of psycho-
logical and physical symptoms with lower adherence. The 
influence of side effects on adherence have been documented 
with mixed results. Most oncology adherence studies have 
involved women with breast cancer on tamoxifen or aro-
matase inhibitors or patients with chronic myeloid leukemia 
on targeted oral agents.4 This limits a discussion of whether 
side effects affect oral medications in general. Virtually all 
studies, including ours, included concomitant measures of 
adherence and symptoms/side effects in which attribution of 
the side effect to the oral agent or another etiology is not clear. 
Nonetheless, high symptom burden is likely to affect self-
administration of oral medications, just as severe symptoms 
prompt emergency department visits and unscheduled admis-
sions for patients with cancer seeking assistance.19 Hershman 
et al20 reported significantly earlier discontinuation of adjuvant 
hormonal therapy in unmarried (vs married) women with 
breast cancer. In contrast to our findings, patients with chronic 
myeloid leukemia in Belgium were evaluated during therapy 
with oral imatinib, and the study reported lower adherence in 
Table 2 item response frequencies of nonadherent behavior on the MMAs-8 adapted to the cancer setting
Item Total Control Intervention
N (%) N (%) N (%)
70 39 31
sometimes forget to take OcM? 9 (13) 8 (21) 1 (3)
Over past 2 weeks, any days OcM not taken? 7 (10) 3 (8) 4 (13)
ever cut back or stopped OcM without telling the doctor because you felt worse when taking it? 1 (1) 0 (0) 1 (3)
When traveling, do you forget to bring OcM? 2 (3) 2 (5) 0 (0)
Did you take your OcM yesterday? 7 (10) 4 (10) 3 (10)
When you feel cancer is under control, do you stop taking OcM? 1 (1) 0 (0) 1 (3)
Do you feel hassled about sticking to cancer plan? 6 (9) 4 (10) 2 (6)
How often do you have difficulty remembering to take OCM? 1 (1): sometimes 1 (1) 0 (0)
5 (7): once in a while 5 (13) 0 (0)
have you taken more than regular dose? 1 (1) 1 (3) 0 (0)
Note: n=70.
Abbreviations: MMAs, Morisky Medication Adherence scale; OcM, oral chemotherapy medicine.
Table 3 Univariate odds of low/medium adherence
Variable Univariate
OR (95% CI) P-value
sDs-15+1 vs sDs-15a 1.1 (1.0–1.2) 0.09
PhQ9c+1 vs PhQ9ca 1.2 (1.0–1.4) 0.05
chemotherapy vs hormonal therapy 3.4 (1.2–9.7) 0.03
Female vs male 3.7 (1.3–10.7) 0.02
stage 4 vs stages 0–3 2.3 (0.8–6.7) 0.14
control vs treatment 2.6 (0.9–7.8) 0.09
Working vs not working 0.4 (0.1–1.1) 0.08
#hs vs .hs 1.3 (0.3–4.9) 0.72
Minority vs nonminority 1.3 (0.3–5.9) 0.73
Age +1 vs age 0.9 (0.9–1.0) 0.02
Married/partnered vs not 0.09 (0.02–0.5) 0.004
1-Month increase in time on therapya 1.2 (0.8–1.5) 0.29
Notes: aindicates a one-unit increase in the respective continuous scale; n=70.
Abbreviations: CI, confidence interval; HS, high school; OR, odds ratio; PHQ9C, 
Patient health Questionnaire 9 continuous; sDs-15, 15-item symptom Distress scale.
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older patients and men; however, lower adherence was found 
also in those living without a spouse/partner.21
Working vs not working at the initiation of cancer therapy 
is a demographic variable we have found influential for several 
outcomes;10,19,22 yet we have not found reports from other 
investigators that documented the working status in relationship 
to oral agent adherence. The beneficial influence of working 
may be related to the structure of the workday, in which routine 
daily activities provide a framework into which medication 
self-administration fits well. Vance et al23 reviewed the literature 
on the benefits of employment for health outcomes in those 
with human immunodeficiency virus infection. The authors 
concluded that working promotes neurocognitive reserve and 
that effect may be manifested in several outcomes such as social 
engagement, regular sleep, less depression, and medication 
adherence. Future research in oncology could explore the pro-
tective effect of working in all patients with cancer, particularly 
in those at risk for cognitive impairment.
While the ESRA-C intervention did not directly prompt 
participants to adhere to self-administered oral medications, 
we saw some signal that the intervention was associated with 
higher adherence to oral medications. This was probably 
an indirect effect in that the ESRA-C intervention group 
experienced significantly lower symptom distress10 over 
the course of therapy, and lower depression24 at the end of 
therapy, than the control group, and both of these outcomes 
may have promoted adherence.
Our analysis and results are limited by the lack of racial 
and ethnic diversity in the sample. We did not record or 
include the complexity of dosing schedule, number of pills 
per day, or number of other medications taken, all of which 
may have had an influence on adherence.
When encountering patients who are unmarried or with-
out a partner, clinicians may want to have more in-depth 
conversations about strategies for assuring adherence. The 
Multinational Association of Supportive Care in Cancer Oral 
Agent Teaching Tool25 has been demonstrated to be a useful 
and feasible tool in clinical cancer settings,26 as it covers the 
very type of issues that our findings suggest as contributors 
to nonadherence, notably cancer symptoms.
Conclusion
Nonadherence to therapeutic oral medications self-administered 
by patients with cancer was associated with being unmarried/
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Figure 1 Classification tree: significant partitioning predictive of adherence.
Note: n=70.
Abbreviations: CR, classification rate; med, medium; SDS-15, 15-item Symptom Distress Scale.
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unpartnered. For those who were married/partnered, symptom 
distress, younger age, not working, and female sex all 
contributed to lower adherence. These findings may be used 
to identify patients at risk for nonadherence and subsequently 
provide additional support to these individuals.
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